ATE473003T1 - Tacrolimus enthaltende feste dispersionen - Google Patents

Tacrolimus enthaltende feste dispersionen

Info

Publication number
ATE473003T1
ATE473003T1 AT04762795T AT04762795T ATE473003T1 AT E473003 T1 ATE473003 T1 AT E473003T1 AT 04762795 T AT04762795 T AT 04762795T AT 04762795 T AT04762795 T AT 04762795T AT E473003 T1 ATE473003 T1 AT E473003T1
Authority
AT
Austria
Prior art keywords
solid dispersions
dispersions containing
containing tacrolimus
tacrolimus
solid
Prior art date
Application number
AT04762795T
Other languages
English (en)
Inventor
Per Holm
Tomas Norling
Original Assignee
Lifecycle Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lifecycle Pharma As filed Critical Lifecycle Pharma As
Application granted granted Critical
Publication of ATE473003T1 publication Critical patent/ATE473003T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT04762795T 2003-08-29 2004-08-30 Tacrolimus enthaltende feste dispersionen ATE473003T1 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DKPA200301232 2003-08-29
DKPA200301837 2003-12-11
US52979303P 2003-12-15 2003-12-15
DKPA200400079 2004-01-21
DKPA200400467 2004-03-23
DKPA200400463 2004-03-23
PCT/DK2004/000574 WO2005020994A1 (en) 2003-08-29 2004-08-30 Solid dispersions comprising tacrolimus

Publications (1)

Publication Number Publication Date
ATE473003T1 true ATE473003T1 (de) 2010-07-15

Family

ID=34280179

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04762795T ATE473003T1 (de) 2003-08-29 2004-08-30 Tacrolimus enthaltende feste dispersionen

Country Status (11)

Country Link
US (15) US7994214B2 (de)
EP (2) EP1663217B1 (de)
JP (2) JP4996249B2 (de)
AT (1) ATE473003T1 (de)
AU (2) AU2004267909B2 (de)
BR (2) BRPI0413927B8 (de)
CA (2) CA2537044C (de)
DE (1) DE602004028023D1 (de)
NO (2) NO337869B1 (de)
PL (2) PL1663217T3 (de)
WO (2) WO2005020993A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1641437A4 (de) * 2003-07-09 2009-06-03 Chong Kun Dang Pharm Corp Feste dispersion von tacrolimus
WO2005020993A1 (en) 2003-08-29 2005-03-10 Lifecycle Pharma A/S Modified release compositions comprising tacrolimus
KR100678824B1 (ko) * 2005-02-04 2007-02-05 한미약품 주식회사 용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물
MX2007011494A (es) * 2005-03-17 2007-12-06 Elan Pharma Int Ltd Composiciones inyectables de compuestos inmunosupresores nanoparticulados.
WO2006136175A2 (en) * 2005-06-22 2006-12-28 Lifecycle Pharma A/S Pharmaceutical compositions comprising tacrolimus and a cyp3a4 inhibitor
WO2007042037A1 (en) * 2005-10-07 2007-04-19 Lifecycle Pharma A/S Tacrolimus combination products
FR2894143B1 (fr) * 2005-12-01 2008-05-02 Pierre Fabre Medicament Sa Composition a liberation prolongee de l'actif, son procede de preparation et son utilisation.
US20080031947A1 (en) * 2006-07-24 2008-02-07 Cima Labs Inc. Orally dissolvable/disintegrable lyophilized dosage forms containing protected
EP2067475A4 (de) * 2006-09-26 2010-12-15 Astellas Pharma Inc Tacrolimus-zubereitung mit verzögerter freisetzung
US20090011018A1 (en) * 2006-12-28 2009-01-08 Astellas Pharma Inc., Sustained release formulation for tacrolimus
MX2009010556A (es) * 2007-03-29 2009-10-22 Panacea Biotec Ltd Formas de dosificacion modificada de tacrolimus.
ES2393814T3 (es) 2007-04-04 2012-12-28 Sigmoid Pharma Limited Una composición farmacéutica oral
ITMI20070720A1 (it) * 2007-04-06 2008-10-07 Monteresearch Srl Composizioni orali contenenti tacrolimus in forma amorfa
US20090018175A1 (en) * 2007-04-25 2009-01-15 Itamar Kanari Pharmaceutical excipient complex
CA2685118C (en) 2007-04-26 2016-11-01 Sigmoid Pharma Limited Manufacture of multiple minicapsules
WO2008132712A2 (en) * 2007-05-01 2008-11-06 Sigmoid Pharma Limited Combination pharmaceutical compositions
JP2010526848A (ja) * 2007-05-11 2010-08-05 エフ．ホフマン−ラ ロシュ アーゲー 難溶性薬物用の医薬組成物
HUE033011T2 (hu) 2007-05-30 2017-11-28 Veloxis Pharmaceuticals As Takrolimuszt tartalmazó napi egyszeri orális dózisforma
US12083103B2 (en) 2007-05-30 2024-09-10 Veloxis Pharmaceuticals, Inc. Tacrolimus for improved treatment of transplant patients
AU2008261957A1 (en) * 2007-06-08 2008-12-18 Addrenex Pharmaceuticals, Inc. Extended release formulation and method of treating adrenergic dysregulation
US8124123B2 (en) * 2007-09-05 2012-02-28 Dow Pharmaceutical Sciences, Inc. Controlled release azithromycin solid dosages forms
TW200932240A (en) * 2007-10-25 2009-08-01 Astellas Pharma Inc Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production
WO2009080030A1 (en) * 2007-12-21 2009-07-02 Lifecycle Pharma A/S Treatment of autoimmune hepatitis with a once daily oral dosage form comprising tacrolimus
CL2008000374A1 (es) 2008-02-05 2008-04-04 Igloo Zone Chile S A Composicion farmaceutica que comprende un polvo para suspension oral de tacrolimus o una de sus sales, hidratos o solvatos y excipientes farmaceuticamente aceptables; procedimiento de preparacion de dicha composicion farmaceutica; y uso para la preve
US12403095B2 (en) * 2008-05-30 2025-09-02 Veloxis Pharmaceuticals, Inc. Stabilized tacrolimus composition
CA2729948C (en) * 2008-07-08 2021-11-23 Lifecycle Pharma A/S Tacrolimus for improved treatment of transplant patients
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
JP2012505211A (ja) * 2008-10-10 2012-03-01 アルヴィン ファーマシューティカルズ インコーポレーティッド チモーゲンの迅速な活性化を促進する剤形
US9775802B2 (en) 2009-03-24 2017-10-03 Bausch & Lomb Incorporated Method for preparing suspensions of low-solubility materials
ES2530049T3 (es) 2009-05-18 2015-02-26 Sigmoid Pharma Limited Composición que comprende gotas de aceite
CN102573802A (zh) 2009-08-12 2012-07-11 希格默伊德药业有限公司 包含聚合物基质和油相的免疫调节组合物
TWI510238B (zh) * 2010-02-17 2015-12-01 Lifecycle Pharma As 穩定化他克莫司（ｔａｃｒｏｌｉｍｕｓ）組合物
ES2665467T3 (es) 2010-03-29 2018-04-25 Astellas Pharma Inc. Composición farmacéutica de liberación modificada
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
WO2012078746A2 (en) * 2010-12-07 2012-06-14 The Johns Hopkins University Compositions and methods for mobilizing stem cells
KR20130028824A (ko) * 2011-09-09 2013-03-20 주식회사 삼양바이오팜 타크로리무스를 포함하는 고체 분산체 및 이의 제조방법
RU2635466C2 (ru) * 2012-04-08 2017-11-13 Теракоат Лтд Препараты термообратимого гидрогеля для применения при лечении нарушений уротелия
US9078925B2 (en) * 2012-06-18 2015-07-14 Galephar Pharmaceutical Research, Inc. Pharmaceutical semi-solid composition of isotretinoin
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
CN104603138A (zh) * 2012-07-12 2015-05-06 艾伯维公司 Hcv抑制剂的晶形
CN113842362A (zh) 2012-11-14 2021-12-28 格雷斯公司 含有生物活性材料与无序无机氧化物的组合物
CN105658217B (zh) 2013-04-29 2021-03-19 约翰霍普金斯大学 经由自体干细胞动员的创伤愈合
US9168246B2 (en) 2013-06-27 2015-10-27 Veloxis Pharmaceutical A/S Regimen for suppressing organ rejection
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
JP6716582B2 (ja) 2014-11-07 2020-07-01 サブリミティ・セラピューティクス・リミテッドＳｕｂｌｉｍｉｔｙ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ シクロスポリンを含む組成物
ES3063790T3 (en) 2015-06-09 2026-04-20 Lonza Sales Ag Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
US20180243224A1 (en) * 2015-08-19 2018-08-30 Vivus, Inc. Pharmaceutical formulations
GB201600376D0 (en) 2016-01-08 2016-02-24 Chronos Therapeutics Ltd Novel therapeutic agents
US10618547B2 (en) * 2017-09-26 2020-04-14 Steering Solutions Ip Holding Corporation Regenerative current limiting of DC machines
WO2020012498A1 (en) 2018-07-13 2020-01-16 Council Of Scientific & Industrial Research Solid dispersion comprising an anticancer compound with improved solubility and efficacy
BR112021004199A2 (pt) * 2018-09-07 2021-05-25 R.P. Scherer Technologies, Llc estabilização de formas de dosagem à base de lipídio sólido ou semissólido através da cura e da adição de tensoativo(s) de baixo teor de hlb
JP7291220B2 (ja) 2018-11-21 2023-06-14 トレモ― ファーマシューティカルズ，インコーポレーテッド ロフェコキシブの精製形態、製造方法および使用
EP3930713B1 (de) 2018-12-04 2025-05-28 Ilko Ilaç Sanayi Ve Ticaret Anonim Sirketi Stabile tacrolimus-salbenformulierung zur topischen behandlung von hauterkrankungen
EP3934677A4 (de) 2019-03-13 2022-11-16 University of Virginia Patent Foundation Zusammensetzungen und verfahren zur förderung der insellebensfähigkeit und zur steigerung der insulinsekretion
JP7646560B2 (ja) 2019-03-18 2025-03-17 サンスター アメリカス インク オーラルケア組成物
GR1009790B (el) * 2019-03-20 2020-08-03 Φαρματεν Α.Β.Ε.Ε. Σκευασμα παρατεταμενης αποδεσμευσης που περιλαμβανει τακρολιμους
US10752642B1 (en) 2019-04-30 2020-08-25 George Mason University Macrocyclic lactones
EP3861989A1 (de) * 2020-02-07 2021-08-11 Bayer Aktiengesellschaft Pharmazeutische zusammensetzung mit regorafenib und stabilisierungsmittel
US11666560B2 (en) 2020-09-24 2023-06-06 George Mason University Anti-fibrotic agent
WO2022187379A1 (en) 2021-03-03 2022-09-09 Sana Biotechnology, Inc. Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions
CA3211799A1 (en) * 2021-03-12 2022-09-15 Robert O. Williams Iii Methods to prepare dry powders using suspension based thin film freezing
CN114469847B (zh) * 2021-12-29 2024-08-13 北京鑫开元医药科技有限公司 他克莫司栓剂及其制备方法和用途
CN116159034B (zh) * 2023-04-23 2023-07-04 国药集团川抗制药有限公司 一种他克莫司缓释胶囊及其制备方法
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925231A (ja) 1983-07-11 1984-02-09 Hitachi Ltd シリコンウエ−ハ
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
JPH0650393B2 (ja) 1985-07-30 1994-06-29 日本合成ゴム株式会社 ポジ型放射線感応性組成物
GB8608080D0 (en) 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
KR0177158B1 (ko) 1990-03-01 1999-03-20 후지사와 도모기찌로 면역억제 활성을 갖는 트리사이클릭 화합물 함유 용액 제제
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
US5601844A (en) 1992-11-18 1997-02-11 Fujisawa Pharmaceutical Co., Ltd. Sustained release medicinal preparation
JPH06227732A (ja) 1993-02-02 1994-08-16 Sharp Corp 複写機におけるシート後処理装置
US6204243B1 (en) 1993-09-01 2001-03-20 Novatis Ag Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
PT956034E (pt) * 1996-07-30 2002-12-31 Novartis Ag Composicoes farmaceuticas para o tratamento da rejeicao de transplantes estados inflamatorios ou auto-imunes compreendendo ciclosporina a e 40-o-(2-hidroxietil)-rapamicina
TW426516B (en) 1996-12-06 2001-03-21 Fujisawa Pharmaceutical Co An oral pharmaceutical composition in solid dispersion containing water-insoluble tricyclic compounds
TW450810B (en) 1997-02-20 2001-08-21 Fujisawa Pharmaceutical Co Macrolides antibiotic pharmaceutical composition for preventing and treating skin diseases
ME00189B (me) 1998-03-26 2011-02-10 Astellas Pharma Inc Preparati sa neprekidnim oslobađanjem
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6168806B1 (en) * 1999-03-05 2001-01-02 Fang-Yu Lee Orally administrable nifedipine pellet and process for the preparation thereof
JP3405261B2 (ja) 1999-03-30 2003-05-12 トヨタ自動車株式会社 筒内噴射式火花点火内燃機関
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB0007842D0 (en) 2000-03-31 2000-05-17 Spruce Barbara Sigma receptor ligands and their medical uses
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
US6761895B2 (en) 2000-04-17 2004-07-13 Yamanouchi Pharmaceutical Co., Ltd. Drug delivery system for averting pharmacokinetic drug interaction and method thereof
EP1275373A4 (de) 2000-04-17 2007-04-04 Astellas Pharma Inc Arzneistoffabgabesystem zur vermeidung von pharmakokinetischen wechselwirkungen zwischen wirkstoffen und methode hierzu
US20020028240A1 (en) 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration
EP1289560A1 (de) 2000-06-12 2003-03-12 SmithKline Beecham Corporation Neue feste dispersionszusammensetzungen
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
WO2003004001A1 (en) * 2001-07-06 2003-01-16 Lifecycle Pharma A/S Controlled agglomeration
US20030129250A1 (en) * 2001-11-20 2003-07-10 Advanced Inhalation Research Inc. Particulate compositions for improving solubility of poorly soluble agents
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
EP1641437A4 (de) 2003-07-09 2009-06-03 Chong Kun Dang Pharm Corp Feste dispersion von tacrolimus
WO2005020993A1 (en) 2003-08-29 2005-03-10 Lifecycle Pharma A/S Modified release compositions comprising tacrolimus
US8591946B2 (en) 2003-08-29 2013-11-26 Veloxis Pharmaceuticals A/S Modified release compositions comprising tacrolimus
EP1675576A1 (de) 2003-10-03 2006-07-05 LifeCycle Pharma A/S Verfahren zur herstellung von pharmazeutischen zusammensetzungen mit modifizierter freisetzung
NO320286B1 (no) 2003-11-19 2005-11-21 Dag Herman Zeiner-Gundersen Turbin for kraftproduksjon
US20050249799A1 (en) 2004-03-03 2005-11-10 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs
US20060045865A1 (en) 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
CA2590675A1 (en) 2004-12-15 2006-06-22 Elan Pharma International Ltd. Nanoparticulate tacrolimus formulations
MX2007011494A (es) 2005-03-17 2007-12-06 Elan Pharma Int Ltd Composiciones inyectables de compuestos inmunosupresores nanoparticulados.
HUE033011T2 (hu) 2007-05-30 2017-11-28 Veloxis Pharmaceuticals As Takrolimuszt tartalmazó napi egyszeri orális dózisforma
US8383135B2 (en) 2010-12-03 2013-02-26 Richard C. Fuisz Solid dosage form that promotes reliable oral, esophageal and GI transit

Also Published As

Publication number Publication date
BRPI0414000A (pt) 2006-10-24
US20140065225A1 (en) 2014-03-06
US8889186B2 (en) 2014-11-18
US20130189318A1 (en) 2013-07-25
JP2007504102A (ja) 2007-03-01
AU2004267909B2 (en) 2008-12-18
US8486993B2 (en) 2013-07-16
US7994214B2 (en) 2011-08-09
BRPI0413927B8 (pt) 2021-05-25
AU2004267909A1 (en) 2005-03-10
US9763920B2 (en) 2017-09-19
US9757362B2 (en) 2017-09-12
BRPI0413927A (pt) 2006-10-24
WO2005020993A1 (en) 2005-03-10
US9161907B2 (en) 2015-10-20
CA2537041C (en) 2012-04-03
US8889185B2 (en) 2014-11-18
US20110251231A1 (en) 2011-10-13
NO334986B1 (no) 2014-08-18
CA2537044A1 (en) 2005-03-10
US20180228779A1 (en) 2018-08-16
PL1663216T3 (pl) 2012-03-30
EP1663216A1 (de) 2006-06-07
US20180214422A1 (en) 2018-08-02
JP4996249B2 (ja) 2012-08-08
US11129815B2 (en) 2021-09-28
NO337869B1 (no) 2016-07-04
US20100008984A1 (en) 2010-01-14
US8586084B2 (en) 2013-11-19
US20160243090A1 (en) 2016-08-25
US8623411B2 (en) 2014-01-07
US10548880B2 (en) 2020-02-04
US20110256190A1 (en) 2011-10-20
AU2004267910A1 (en) 2005-03-10
CA2537041A1 (en) 2005-03-10
EP1663217B1 (de) 2010-07-07
PL1663217T3 (pl) 2010-12-31
US20110263632A1 (en) 2011-10-27
US8617599B2 (en) 2013-12-31
WO2005020994A1 (en) 2005-03-10
EP1663216B1 (de) 2011-11-02
US11077096B2 (en) 2021-08-03
NO20061429L (no) 2006-05-29
US20140066473A1 (en) 2014-03-06
US8623410B2 (en) 2014-01-07
US20110250277A1 (en) 2011-10-13
US20140073665A1 (en) 2014-03-13
CA2537044C (en) 2012-04-17
BRPI0413927B1 (pt) 2019-11-12
BRPI0414000B1 (pt) 2019-11-05
JP2011251972A (ja) 2011-12-15
NO20061430L (no) 2006-05-29
BRPI0414000B8 (pt) 2021-05-25
AU2004267910B2 (en) 2011-01-06
US20160166551A1 (en) 2016-06-16
EP1663217A1 (de) 2006-06-07
DE602004028023D1 (de) 2010-08-19
HK1096032A1 (en) 2007-05-25
US20110251232A1 (en) 2011-10-13
US20200289478A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
ATE473003T1 (de) Tacrolimus enthaltende feste dispersionen
WO2006108075A3 (en) Compositions and methods for enhancing drug sensitivity and treating drug resistant infections an diseases
CY1120831T1 (el) Μεθοδοι μειωσης της συσσωματωσης toy il-1ra
WO2007076062A3 (en) Protein formulations with reduced viscosity and uses thereof
AP2507A (en) Quinoline derivatives and use thereof as mycobacterial inhibitors.
WO2005065657A3 (en) Solid compositions of low-solubility drugs and poloxamers
DK1663217T3 (da) Faste dispersioner indeholdende tacrolimus
WO2005065241A3 (en) Smmr (small molecule metabolite reporters) for use as in vivo glucose biosensors
MY145148A (en) Pharmaceutical formulation comprising an antibiotic, a triazole and a carticosteroid
WO2005123076A3 (en) Pharmaceutical compositions
WO2005009975A3 (en) Benzimidazole derivatives as mek inhibitors
CA2541931A1 (en) Microcapsules and emulsions containing low bloom gelatin and methods of making and using thereof
ECSP088203A (es) Dispersiones amorfas sólidas
EP1663959A4 (de) Neue amidinverbindungen zur behandlung mikrobieller infektionen
EA201200934A1 (ru) Противораковые комбинации лекарственных средств на основе артемизинина с другими химиотерапевтическими агентами
WO2005021706A3 (en) Delivery of compounds with rehydrated blood cells
WO2008033987A3 (en) Compositions and methods to prevent cancer with cupredoxins
WO2005041747A3 (en) Stealthy nano agents
ATE434639T1 (de) Wässrige dispersionen von silikon-polyether- blockcopolymeren
WO2008081829A1 (ja) 難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーｅ
WO2009026257A3 (en) Methods and compositions for controlling the bioavailability of poorly soluble drugs
AP2188A (en) Substituted quinolines and their use as mycobacterial inhibitors.
WO2006097617A3 (fr) Nouveaux derives dihydropyrimidines et leur utilisation comme agents anti-cancereux
NO20076120L (no) Stabile nanopartikkelformuleringer
WO2008054341A3 (en) Method of bioimaging using nanocrystals of fluorescent dyes

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1663217

Country of ref document: EP